Last $3.88 USD
Change Today -0.04 / -1.02%
Volume 127.3K
NNVC On Other Exchanges
Symbol
Exchange
NYSE Amex
Berlin
As of 8:04 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

nanoviricides inc (NNVC) Snapshot

Open
$3.89
Previous Close
$3.92
Day High
$3.94
Day Low
$3.83
52 Week High
09/25/13 - $7.59
52 Week Low
02/11/14 - $2.67
Market Cap
211.9M
Average Volume 10 Days
149.5K
EPS TTM
$-0.20
Shares Outstanding
54.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOVIRICIDES INC (NNVC)

Related News

No related news articles were found.

nanoviricides inc (NNVC) Related Businessweek News

No Related Businessweek News Found

nanoviricides inc (NNVC) Details

NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.

6 Employees
Last Reported Date: 10/8/13
Founded in 2005

nanoviricides inc (NNVC) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $275.0K
Chairman, President and Secretary
Total Annual Compensation: $275.0K
Interim Chief Finance Officer and Principal A...
Total Annual Compensation: $12.0K
Compensation as of Fiscal Year 2013.

nanoviricides inc (NNVC) Key Developments

NanoViricides Opens New R&D and cGMP Pilot Manufacturing Facility in Connecticut

NanoViricides Inc. announced the opening of its new R&D and cGMP pilot manufacturing facility in Connecticut on 21 July 2014. According to the company, this opening will create high-skill jobs in Connecticut, as well as the advancement of truly groundbreaking medical technologies.

NanoViricides, Inc.(AMEX:NNVC) added to Russell 2000 Index

NanoViricides, Inc. will be added to the Russell 2000 Index.

NanoViricides, Inc.(AMEX:NNVC) added to Russell 3000 Index

NanoViricides, Inc. will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNVC:US $3.88 USD -0.04

NNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNVC.
View Industry Companies
 

Industry Analysis

NNVC

Industry Average

Valuation NNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOVIRICIDES INC, please visit www.nanoviricides.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.